MedImmune and Micromet have initiated a Phase I trial of MEDI-565 (MT111) in patients with advanced gastrointestinal cancers.

The dose-escalation study is designed to evaluate the safety, tolerability, and anti-tumour activity of the product candidate in adults with advanced gastrointestinal cancers.

Dose escalation in subsequent cohorts will be based on safety and tolerability.

After the maximum tolerated dose is established, additional study subjects with refractory colorectal or pancreatic cancer will be included in a dose-expansion phase to further assess the safety and anti-tumour activity.

MEDI-565 (MT111) is a BiTE antibody designed to direct a patient’s T cells, the body’s most potent killer cells, against cancer cells that express carcinoembryonic antigen.